Regeneron Pharmaceuticals is a biotech heavyweight with over 35 years of operation and more than 15,000 employees. Founded and still led by physician-scientists, the company invents, develops, and commercializes medicines for serious diseases, with a pipeline built on proprietary platforms like VelociSuite® for antibody discovery and the Regeneron Genetics Center® for genetic medicine and data-powered insights. The scale is real: over 1,400 team members hold MDs and/or PhDs.
For cybersecurity practitioners, the threat model here isn't abstract. You're protecting proprietary biotech IP - antibody discovery pipelines, genomic datasets, and clinical trial data - at a company where the science-to-medicine translation cycle is the core business function. The attack surface spans research infrastructure, manufacturing systems, and a global operational network. This isn't a fintech doing compliance theater; it's a high-value target handling regulated health data, trade secrets, and the kind of biological research intelligence that nation-state actors actively pursue.
The security team operates across domains that matter: securing data platforms powering genetic research, safeguarding antibody discovery technology, and maintaining the integrity of systems where a breach could compromise years of R&D. Tooling and team structure reflect the stakes - this is a shop where cybersecurity directly enables the science, not a cost center bolted onto the org chart.
